From Insight to Action | Pharmacy & Clinical Lens
Identifying a polypharmacy risk earns a checkmark on a report. Resolving it earns a healthier patient. The two outcomes get treated as the same thing far too often, and July is when that distinction shows up in the data.
The gap between flagging a risk and resolving it is well documented. A systematic review of deprescribing trials found that even when a therapy evaluation reaches a prescriber, implementation rates for the recommended change range anywhere from 24% to 67%. In other words, a flag is a starting point, not a result. Most of the work of “fixing it” happens after the recommendation lands on someone’s desk.
June’s midyear review flagged interaction risks, deprescribing candidates, and prescribing patterns worth a second look. July tracks what happened next: which flags reached a physician, which physicians responded, and which cases closed.
Recent research reinforces why the delivery model matters as much as the flag itself. A 2026 study covered by Medscape found that deprescribing education aimed at both patients and physicians together outperformed outreach to physicians alone. Closing a loop takes more than a notification; it takes a channel built for a response.
RazorMetrics routes every polypharmacy case directly to the prescriber, backed by a 75% physician response rate, well above the implementation ranges typically reported in the clinical literature. That response rate carries the real weight: a risk identified and left untouched protects no one.
Closed polypharmacy cases. Completed deprescribing conversations. Interactions resolved instead of merely noted. Each is a measurable outcome, not a line item on a risk report.
Finding the risk and resolving it are two different jobs. RazorMetrics does both, and July is the proof.
Ask your RazorMetrics team for a free analysis of your polypharmacy risk today.
